FindTrial
Sign In

Two-way observational real world study of prognosis and antibiotic type association in patients with high-risk sepsis multiresistant bacterial infection

Two-way observational real world study of prognosis and antibiotic type association in patients with high-risk sepsis multiresistant bacterial infection

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500110183
Enrollment
Unknown
Registered
2025-10-10
Start date
2025-11-01
Completion date
Unknown
Last updated
2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sepsis

Interventions

Critical illness group:NA

Sponsors

Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients with multiple risk factors for multidrug-resistant bacterial infection (such as chronic obstructive pulmonary disease, immune dysfunction, diabetes, etc.); 2. Patients with infection and SOFA score greater than or equal to 2; 3. Age greater than 18 years; 4. Patients who have used antibiotics more than one dose.

Exclusion criteria

Exclusion criteria: 1. Fungal culture positive patient; 2. End-stage palliative care patients; 3. Patients who were allergic to elazolin and discontinued the drug; 4. Patients who developed adverse reactions such as liver and kidney function impairment and stopped taking the drug.

Design outcomes

Primary

MeasureTime frame
The clinical response rate on the 14th;—

Secondary

MeasureTime frame
Microbiological efficacy;Comprehensive efficacy;—

Countries

China

Contacts

Public ContactZhengfei Yang

Sun Yat-sen Memorial Hospital, Sun Yat-sen University

yangzhengfei@vip.163.com+86 136 3237 0949

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026